My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 204

    1.

    The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism.

    Holst JJ, Orskov C.

    Diabetes. 2004 Dec;53 Suppl 3:S197-204. Review.PMID: 15561911 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Incretins and other peptides in the treatment of diabetes.

    Todd JF, Bloom SR.

    Diabet Med. 2007 Mar;24(3):223-32. Review.PMID: 17263764 [PubMed - indexed for MEDLINE]Related articles

    3.

    Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.

    Holst JJ.

    Expert Opin Emerg Drugs. 2004 May;9(1):155-66. Review.PMID: 15155141 [PubMed - indexed for MEDLINE]Related articles

    4.

    Enhancing incretin action for the treatment of type 2 diabetes.

    Drucker DJ.

    Diabetes Care. 2003 Oct;26(10):2929-40. Review.PMID: 14514604 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Harnessing the therapeutic potential of glucagon-like peptide-1: a critical review.

    Baggio LL, Drucker DJ.

    Treat Endocrinol. 2002;1(2):117-25. Review.PMID: 15765627 [PubMed - indexed for MEDLINE]Related articles

    6.

    GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.

    Hansotia T, Drucker DJ.

    Regul Pept. 2005 Jun 15;128(2):125-34. Review.PMID: 15780432 [PubMed - indexed for MEDLINE]Related articles

    7.

    Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.

    Vilsbøll T, Krarup T, Sonne J, Madsbad S, Vølund A, Juul AG, Holst JJ.

    J Clin Endocrinol Metab. 2003 Jun;88(6):2706-13.PMID: 12788877 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes.

    Gautier JF, Fetita S, Sobngwi E, Salaün-Martin C.

    Diabetes Metab. 2005 Jun;31(3 Pt 1):233-42. Review.PMID: 16142014 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    The entero-insular axis in type 2 diabetes--incretins as therapeutic agents.

    Creutzfeldt W.

    Exp Clin Endocrinol Diabetes. 2001;109 Suppl 2:S288-303. Review.PMID: 11460578 [PubMed - indexed for MEDLINE]Related articles

    10.

    [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2]

    Diamant M, Bunck MC, Heine RJ.

    Ned Tijdschr Geneeskd. 2004 Sep 25;148(39):1912-7. Review. Dutch. PMID: 15495988 [PubMed - indexed for MEDLINE]Related articles

    11.

    Glucagon-like peptide-1 as a treatment option for type 2 diabetes and its role in restoring beta-cell mass.

    Gallwitz B.

    Diabetes Technol Ther. 2005 Aug;7(4):651-7. Review.PMID: 16120042 [PubMed - indexed for MEDLINE]Related articles

    12.

    Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1.

    Holst JJ.

    Diabetes Metab Res Rev. 2002 Nov-Dec;18(6):430-41. Review.PMID: 12469357 [PubMed - indexed for MEDLINE]Related articles

    13.

    beta-cell failure in diabetes and preservation by clinical treatment.

    Wajchenberg BL.

    Endocr Rev. 2007 Apr;28(2):187-218. Epub 2007 Mar 12. Review.PMID: 17353295 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.

    Pospisilik JA, Martin J, Doty T, Ehses JA, Pamir N, Lynn FC, Piteau S, Demuth HU, McIntosh CH, Pederson RA.

    Diabetes. 2003 Mar;52(3):741-50.PMID: 12606516 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans.

    Holst JJ, Gromada J.

    Am J Physiol Endocrinol Metab. 2004 Aug;287(2):E199-206. Review.PMID: 15271645 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid.

    Green BD, Gault VA, Flatt PR, Harriott P, Greer B, O'Harte FP.

    Arch Biochem Biophys. 2004 Aug 15;428(2):136-43.PMID: 15246869 [PubMed - indexed for MEDLINE]Related articles

    17.

    The entero-insular axis: implications for human metabolism.

    Ranganath LR.

    Clin Chem Lab Med. 2008;46(1):43-56. Review.PMID: 18020966 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs.

    Deacon CF, Wamberg S, Bie P, Hughes TE, Holst JJ.

    J Endocrinol. 2002 Feb;172(2):355-62.PMID: 11834453 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Therapies for the treatment of type 2 diabetes mellitus based on incretin action.

    Gallwitz B.

    Minerva Endocrinol. 2006 Jun;31(2):133-47. Review.PMID: 16682937 [PubMed - indexed for MEDLINE]Related articles

    20.

    Gut peptides in the treatment of diabetes mellitus.

    Vahl TP, D'Alessio DA.

    Expert Opin Investig Drugs. 2004 Mar;13(3):177-88. Review.PMID: 15013938 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity